ADAM15 suppresses cell motility by driving integrin α5β1 cell surface expression via Erk inactivation

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 10, 2008, Pages 2164-2173

  Chen, Qin ^a   Meng, Ling hua ^a   Zhu, Cai hua ^a   Lin, Li ping ^a   Lu, He ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

ADAM15; Erk1 2; Integrin; Metastasis; Migration

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADAM PROTEIN; ADAM15 PROTEIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SMALL INTERFERING RNA; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL SURFACE; CHINESE HAMSTER; CHO CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; STAINING;

ADAM PROTEINS; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRONECTINS; HUMANS; INTEGRIN ALPHA5BETA1; LUNG NEOPLASMS; MELANOMA; MEMBRANE PROTEINS; MICE; TRANSPLANTATION, HETEROLOGOUS;

EID: 48949117184     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.02.021     Document Type: Article

References (26)

1. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. The Journal of Biological Chemistry 270 46 (1995) 27489-27494
2. Beck V., Herold H., Benge A., Luber B., Hutzler P., Tschesche H., et al. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. The International Journal of Biochemistry & Cell Biology 37 3 (2005) 590-603
3. Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., and Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International Journal of Oncology 26 1 (2005) 17-24
4. Charrier L., Yan Y., Nguyen H.T., Dalmasso G., Laboisse C.L., Gewirtz A.T., et al. ADAM-15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells. The Journal of Biological Chemistry 282 23 (2007) 16948-16958
5. Cluzel C., Saltel F., Lussi J., Paulhe F., Imhof B.A., and Wehrle-Haller B. The mechanisms and dynamics of (alpha)v(beta)3 integrin clustering in living cells. The Journal of Cell Biology 171 2 (2005) 383-392
6. Dudley D.T., Pang L., Decker S.J., Bridges A.J., and Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences of the United States of America 92 17 (1995) 7686-7689
7. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clinical & Experimental Metastasis 20 3 (2003) 203-213
8. Guo H.B., Lee I., Bryan B.T., and Pierce M. Deletion of mouse embryo fibroblast N-acetylglucosaminyltransferase V stimulates alpha5beta1 integrin expression mediated by the protein kinase C signaling pathway. The Journal of Biological Chemistry 280 9 (2005) 8332-8342
9. Ham C., Levkau B., Raines E.W., and Herren B. ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherin. Experimental Cell Research 279 2 (2002) 239-247
10. Herren B., Garton K.J., Coats S., Bowen-Pope D.F., Ross R., and Raines E.W. ADAM15 overexpression in NIH3T3 cells enhances cell-cell interactions. Experimental Cell Research 271 1 (2001) 152-160
11. Horiuchi K., Weskamp G., Lum L., Hammes H.P., Cai H., Brodie T.A., et al. Potential role for ADAM15 in pathological neovascularization in mice. Molecular and Cellular Biology 23 16 (2003) 5614-5624
12. Howard L., Nelson K.K., Maciewicz R.A., and Blobel C.P. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. The Journal of Biological Chemistry 274 44 (1999) 31693-31699
13. Hughes P.E., Renshaw M.W., Pfaff M., Forsyth J., Keivens V.M., Schwartz M.A., et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88 4 (1997) 521-530
14. Karkkainen I., Karhu R., and Huovila A.P. Assignment of the ADAM15 gene to human chromosome band 1q21.3 by in situ hybridisation. Cytogenetics and Cell Genetics 88 3/4 (2000) 206-207
15. Kratzschmar J., Lum L., and Blobel C.P. Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence. The Journal of Biological Chemistry 271 9 (1996) 4593-4596
16. Kuefer R., Day K.C., Kleer C.G., Sabel M.S., Hofer M.D., Varambally S., et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia (New York, NY) 8 4 (2006) 319-329
17. Martin J., Eynstone L.V., Davies M., Williams J.D., and Steadman R. The role of ADAM 15 in glomerular mesangial cell migration. The Journal of Biological Chemistry 277 37 (2002) 33683-33689
18. Nath D., Slocombe P.M., Stephens P.E., Warn A., Hutchinson G.R., Yamada K.M., et al. Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Journal of Cell Science 112 Pt 4 (1999) 579-587
19. Palecek S.P., Loftus J.C., Ginsberg M.H., Lauffenburger D.A., and Horwitz A.F. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 385 6616 (1997) 537-540
20. Poghosyan Z., Robbins S.M., Houslay M.D., Webster A., Murphy G., and Edwards D.R. Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. The Journal of Biological Chemistry 277 7 (2002) 4999-5007
21. Schutz A., Hartig W., Wobus M., Grosche J., Wittekind C., and Aust G. Expression of ADAM15 in lung carcinomas. Virchows Archives 446 4 (2005) 421-429
22. Takada Y., Ylanne J., Mandelman D., Puzon W., and Ginsberg M.H. A point mutation of integrin beta 1 subunit blocks binding of alpha 5 beta 1 to fibronectin and invasin but not recruitment to adhesion plaques. The Journal of Cell Biology 119 4 (1992) 913-921
23. Takagi J., Kamata T., Meredith J., Puzon-McLaughlin W., and Takada Y. Changing ligand specificities of alphavbeta1 and alphavbeta3 integrins by swapping a short diverse sequence of the beta subunit. The Journal of Biological Chemistry 272 32 (1997) 19794-19800
24. Trochon-Joseph V., Martel-Renoir D., Mir L.M., Thomaidis A., Opolon P., Connault E., et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Research 64 6 (2004) 2062-2069
25. Wu E., Croucher P.I., and McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochemical and Biophysical Research Communications 235 2 (1997) 437-442
26. Zhang X.P., Kamata T., Yokoyama K., Puzon-McLaughlin W., and Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. The Journal of Biological Chemistry 273 13 (1998) 7345-7350